NAS:SGMO (USA) Also trade in: Germany Switzerland UK

Sangamo Therapeutics Inc

$ 9.31 -0.29 (-3.02%)
Volume: 762,823 Avg Vol (1m): 1,935,920
Market Cap $: 1.07 Bil Enterprise Value $: 723.71 Mil
P/E (TTM): 0.00 P/B: 2.91
Earnings Power Value -7.43
Net Current Asset Value 1.45
Tangible Book 2.31
Projected FCF -0.07
Median P/S Value 14
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked lower than
53.62% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SGMO: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.71, Med: 10000, Max: 10000
Current: 10000
1.71
10000
Equity-to-Asset 0.61
Equity-to-Asset ranked lower than
57.54% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SGMO: 0.61
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.39, Med: 0.87, Max: 0.99
Current: 0.61
0.39
0.99
Debt-to-EBITDA -0.28
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
SGMO: -0.28
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.45, Med: -0.37, Max: -0.06
Current: -0.28
-0.45
-0.06
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.47
DISTRESS
GREY
SAFE
Beneish M-Score 0.12
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 14.04%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -125.44
Operating Margin ranked higher than
50.13% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SGMO: -125.44
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -374.23, Med: -114.59, Max: -58.38
Current: -125.44
-374.23
-58.38
Net Margin % -113.21
Net Margin ranked higher than
50.63% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SGMO: -113.21
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -369.58, Med: -106.63, Max: -57.59
Current: -113.21
-369.58
-57.59
ROE % -27.44
ROE ranked higher than
59.45% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SGMO: -27.44
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -52.56, Med: -29.97, Max: -16.09
Current: -27.44
-52.56
-16.09
ROA % -17.05
ROA ranked higher than
64.48% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SGMO: -17.05
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -47.56, Med: -24.25, Max: -13.76
Current: -17.05
-47.56
-13.76
ROC (Joel Greenblatt) % -229.13
ROC (Joel Greenblatt) ranked higher than
57.63% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SGMO: -229.13
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2186.87, Med: -1515.43, Max: -140.54
Current: -229.13
-2186.87
-140.54
3-Year Total Revenue Growth Rate 28.80
3-Year Revenue Growth Rate ranked lower than
63.75% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
SGMO: 15.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -37.3, Med: -2.15, Max: 67.4
Current: 15.4
-37.3
67.4
3-Year Total EBITDA Growth Rate -17.70
3-Year EBITDA Growth Rate ranked lower than
74.69% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
SGMO: -5.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -104.7, Med: -5.05, Max: 23.3
Current: -5.5
-104.7
23.3
3-Year EPS w/o NRI Growth Rate -6.50
3-Year EPS w/o NRI Growth Rate ranked lower than
76.15% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
SGMO: -6.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -184.4, Med: -3.7, Max: 25.2
Current: -6.5
-184.4
25.2

» SGMO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SGMO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare SZSE:000403 SHSE:600645 SZSE:300149 ASX:CUV ROCO:4147 SZSE:002275 NAS:EIDX NAS:ATNX XKRX:095700 NAS:ATRA NAS:EDIT NAS:EPZM XKRX:006280 NAS:CORT XMAD:ROVI NAS:CDXS NAS:APLS NAS:TPTX NAS:TBPH NAS:VCYT
Traded in other countries GBY.Germany 0R1D.UK
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc was incorporated in the State of Delaware on June 22, 1995. The Company is engaged in translating ground-breaking science into genomic therapies that transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and highly specific genome editing and gene regulation, and are developing genome editing and gene therapies for the treatment of genetically tractable diseases.

Ratios

Current vs industry vs history
PB Ratio 2.91
PB Ratio ranked higher than
50.00% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SGMO: 2.91
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.47, Med: 3.81, Max: 12.58
Current: 2.91
1.47
12.58
PS Ratio 11.75
PS Ratio ranked lower than
63.50% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SGMO: 11.75
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 4.84, Med: 17.68, Max: 55.08
Current: 11.75
4.84
55.08
Price-to-Operating-Cash-Flow 58.20
Price-to-Operating-Cash-Flow ranked higher than
59.52% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
SGMO: 58.2
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 19.1, Med: 54.67, Max: 140.16
Current: 58.2
19.1
140.16
EV-to-EBIT -7.25
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SGMO: -7.25
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -45.3, Med: -9.3, Max: -0.9
Current: -7.25
-45.3
-0.9
EV-to-EBITDA -7.46
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SGMO: -7.46
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -46.3, Med: -9.6, Max: -0.9
Current: -7.46
-46.3
-0.9
EV-to-Revenue 9.08
EV-to-Revenue ranked lower than
55.90% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SGMO: 9.08
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.3, Med: 13.45, Max: 52.3
Current: 9.08
2.3
52.3
Current Ratio 3.98
Current Ratio ranked higher than
66.48% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SGMO: 3.98
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.98, Med: 10.73, Max: 55.31
Current: 3.98
3.98
55.31
Quick Ratio 3.98
Quick Ratio ranked higher than
66.85% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SGMO: 3.98
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.98, Med: 10.73, Max: 55.31
Current: 3.98
3.98
55.31
Days Sales Outstanding 33.46
Days Sales Outstanding ranked higher than
78.14% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SGMO: 33.46
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 1.14, Med: 32.94, Max: 93.6
Current: 33.46
1.14
93.6

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -11.30
3-Year Share Buyback Rate ranked higher than
68.96% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SGMO: -11.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -61.2, Med: -9.1, Max: -1.1
Current: -11.3
-61.2
-1.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.03
Price-to-Tangible-Book ranked higher than
58.28% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SGMO: 4.03
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.89, Med: 3.82, Max: 12.57
Current: 4.03
0.89
12.57
Price-to-Median-PS-Value 0.67
Price-to-Median-PS-Value ranked lower than
65.19% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SGMO: 0.67
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.33, Med: 1.33, Max: 10.44
Current: 0.67
0.33
10.44
Earnings Yield (Joel Greenblatt) % -13.84
Earnings Yield (Greenblatt) ranked higher than
54.39% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SGMO: -13.84
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -110.2, Med: -10.8, Max: -2.2
Current: -13.84
-110.2
-2.2

More Statistics

Revenue (TTM) (Mil) $ 79.76
EPS (TTM) $ -0.89
Beta 2.28
Volatility % 62.92
52-Week Range $ 6.26 - 19.25
Shares Outstanding (Mil) 115.36

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N